Brendan Jenkins

Professor Brendan Jenkins serves as the Program Lead for Tumour Inflammation & Immunotherapy at the South Australian Immunogenomics Cancer Institute (SAiGENCI), University of Adelaide. He is affiliated with the Faculty of Health and Medical Sciences and leads the Cancer and Immune Signalling Laboratory (CISL). His research focuses on innate immune regulators in inflammation-related cancers and chronic diseases.

• PhD: Hanson Institute/University of Adelaide
• Postdoctoral training: Fred Hutchinson Cancer Research Center (USA), Ludwig Institute for Cancer Research (Melbourne)

Research Interests: Professor Jenkins investigates the roles of innate immune cytokines, proteases, and pattern recognition receptors (e.g., Toll-like receptors) in driving inflammation-associated cancers (lung, gastric, pancreatic) and chronic conditions (gastritis, COPD, pancreatitis). His work bridges basic research, clinical translation, and industry collaboration across Australia, UK, Japan, Singapore, and Europe.

Scientific Recognition: He has held prestigious fellowships and received awards like the Tall Poppy Award and Cytokine and Interferon Society Distinguished Service Award. His work is supported by grants from NHMRC, Cancer Council, US Department of Defense, and international foundations.

Supervision: Eligible to supervise Masters and PhD candidates. Laboratory: Leads the Cancer and Immune Signalling Laboratory (CISL) and directs the Centre for Innate Immunity and Infectious Diseases, focusing on translational immunology research.